The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Wed., Mar. 3, 9:51 PM

Slide #100. Exact Sciences Corp. Ashion Analytics, LLC

Acquirer: Exact Sciences Corp. (NASDAQ:EXAS)
Acquiree: Ashion Analytics, LLC
Details: Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments. The team at Ashion will help accelerate the development of Exact Sciences' precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests.

Exact Sciences is a cancer diagnostics company. Co. has developed several brands in cancer screening and diagnostics, including Cologuard and Oncotype DX. Co. has developed a non-invasive screening test called Cologuard® to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co. is also working on the development of additional tests for other types of cancer. Co. is also focusing its research and development efforts on building a pipeline of potential future products and services with a focus on blood-based tests. Co. is advancing liquid biopsy through biomarker discovery and validation in tissue, blood and other fluids.

EXAS SEC Filing Email Alerts Service


Open the EXAS Page at The Online Investor »

Company Name: 
EXACT Sciences Corp.
Website: 
www.exactsciences.com
Sector: 
Biotechnology
Number of ETFs Holding EXAS: 
57
Total Market Value Held by ETFs: 
$2.32B
Total Market Capitalization: 
$23.71B
% of Market Cap. Held by ETFs: 
9.79%
 

Open the EXAS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.71 out of 4)
70th percentile
(ranked higher than approx. 70% of all stocks covered)

Analysts' Target Price:
EXAS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.